Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile

Connect Biopharma Holdings Limited CNTB has completed its first-in-human Phase 1 study of CBP-174 in healthy adults.
CBP-174, a highly selective, peripherally acting H3 receptor antagonist drug candidate, is in development to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic dermatitis.
CBP-174, administered orally, was observed to be safe and well-tolerated across eight dose escalation cohorts evaluated up to a maximum dose of 16 mg or placebo.
Also See: Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year.
There were no serious adverse events, reported adverse events were predominantly mild in severity, and no dose-limiting toxicities were identified.
Other safety parameters, including vital signs, ECGs, and laboratory results, showed no clinically notable safety findings.
Pharmacokinetics of CBP-174 exhibited rapid absorption with dose-proportional increases in exposure followed by linear elimination.
Price Action: CNTB shares are up 1.05% at $1.45 on the last check Tuesday.